CC
ICPT

Cannell & Co’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Cannell & Co’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-56,265
Closed -$13.6M – 280
2015
Q2 		$13.6M Buy
56,265
+685
+1% +$182K 0.38% 67
2015
Q1 		$15.7M Buy
+55,580
New +$12M 0.45% 60

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Cannell & Co's ICPT Position: Q3 2015 in Review

Cannell & Co sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 56,265 shares — an estimated $13.6M sold.

Cannell & Co first reported a position in ICPT in Q1 2015 and held it in 2 quarters. The position peaked at $15.7M in Q1 2015. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • Cannell & Co reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Cannell & Co sold 56,265 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $13.6M.
  • Cannell & Co first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Cannell & Co's Intercept Pharmaceuticals, Inc. position peaked at $15.7M in Q1 2015.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on Cannell & Co's 13F filing for Q3 2015, filed 13 Nov 2015.